Media

  • Email
  • Help

Information for you

On this page, we highlight information of partcular relevance for media, including news, events and featured information for journalists with a professional interest in the development and availability of medicines in the European Union.

For more information and details relevant for media, see our News & events section. 

For enquiries from media, please contact the EMA press office

Featured information

News for media

Events of interest

  • 18/05/2017 - 19/05/2017

    EMA

    Visit of the East African Community (EAC)

    As part of the European Medicines Agency's (EMA) ongoing collaboration with African regulators, it hosted a delegation from EAC which is one of the most advanced regional economic communities in Africa. It is composed of 6 countries: Burundi, Kenya, Rwanda, South Sudan, Tanzania and Uganda. EAC is an observer in ICH and the International Pharmaceutical Regulators Forum. The delegation included the heads of these six agencies, the EAC Secretariat, and representatives from the World Health Organization and the World Bank. The event discussed the role of EMA in the European medicines regulatory network, focusing on its collaboration with national competent authorities. It also discussed the structure and operation of EMA, internal controls, human resources management, training, information technology and infrastructure, as well as lifecycle management of medicines and medicines approval, veterinary medicines, pharmacovigilance and inspections, committee and procedure management. ... Read more

  • 17/05/2017

    Second 2017 meeting of the coordinating group of the European network of paediatric research at the European Medicines Agency (Enpr-EMA)

    The 2017 face to face meeting of Enpr-EMA networks and coordinating group members takes place after the annual open workshop on 16 May. The networks meeting focuses on the outcome of the open workshop and the action plan for 2017/2018. ... Read more

  • 14/11/2017

    EMA

    Joint European Medicines Agency / Drug Information Association information day on measuring the impact of pharmacovigilance activities

    Measuring the impact of pharmacovigilance is essential to allow regulators and pharmaceutical industry to ensure key pharmacovigilance activities are effective and efficient and to support regulatory decisions. Effective risk minimisation balancing benefits and risks of medicines are important tools for patient empowerment and to achieve best public health outcomes. A workshop in 2016 highlighted the need for a sustainable framework, robust scientific methodologies, timely generation of decision-relevant data and clear roles and responsibilities as key pillars of impact research. Based on these recommendations, PRAC is revising its strategy to evaluate EU pharmacovigilance activities in a collaborative approach with clearly defined process indicators and measures of patient health outcomes. At this event stakeholders discuss methodologies for impact research, enablers and barriers to impact, and foster collaboration and sharing of impact relevant information. ... Read more

  • 19/05/2017

    First anniversary of PRIME: experience so far

    The European Medicines Agency (EMA) launched the PRIME (PRIority Medicines) scheme in March 2016. The scheme provides early and enhanced support to medicines that have the potential to address patients’ unmet needs. This meeting is organised by EMA to review the experience gained with PRIME one year after it was launched. The aim of the meeting is to receive feedback from users and potential users of the scheme, provide information on how the rules on eligibility have been applied and what types of support applicants have received so far and discuss practical examples that illustrate the benefits of PRIME and how it builds on the existing tools.  ... Read more

  • 29/03/2017 - 30/03/2017

    EMA

    Seventh Framework Programme (FP7) small-population research methods projects and regulatory application workshop

    The European Union funds three projects, Asterix, IDeAl and InSPiRe, within the Seventh Framework Programme (FP7) to develop new methodology on design and analysis of small population clinical trials since 2013. The projects are in their final phase. The workshop will discuss their results to date. The aim is to translate and promote results and novel methodologies into tangible recommendations to advance the clinical research and development of medicines and new treatments for patients with a rare disease and personalised medicine. The results to date and draft recommendations for application will be discussed by international representatives of patient organisations, pharmaceutical industry, academic statisticians and clinical trial methodologists, clinical researchers, pharmaceutical industry and regulators. ... Read more

  • See all Events of interest

Information for:

Find information for...